Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms

Spyre Therapeutics, Inc. earns a Strong Buy on Phase 1 wins, IBD/RA pipeline catalysts, and $757M cash runway. Click for this ...